Key result
In Japanese patients with non-valvular atrial fibrillation treated with rivaroxaban, renal dysfunction was associated with a higher incidence of stroke or systemic embolism compared to normal renal function.
Why the study?
This sub-analysis investigated the effectiveness and safety of rivaroxaban in Japanese NVAF patients based on baseline creatinine clearance levels and prescribed rivaroxaban doses.
Does inappropriate dosing of rivaroxaban affect the risk of stroke, bleeding, and mortality in Japanese patients with non-valvular atrial fibrillation and varying renal function?
Observational (n=6,806)
Yes
Does inappropriate dosing of rivaroxaban affect the risk of stroke, bleeding, and mortality in Japanese patients with non-valvular atrial fibrillation and varying renal function?
Appropriate dose reduction of rivaroxaban based on renal function is crucial to balance the risks of bleeding and ischemia in patients with non-valvular atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Inappropriate rivaroxaban dosing may raise mortality or bleeding risks by renal function; observational data leave causal effects open.
The EXPAND Study demonstrated the effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation (NVAF) in routine clinical practice in Japan. This sub-analysis was conducted to reveal the effectiveness and safety of rivaroxaban in Japanese NVAF patients according to baseline creatinine clearance (CrCl) levels and rivaroxaban doses in the EXPAND Study. We examined 6806 patients whose baseline CrCl data were available and classified them into 2 groups: normal renal function group with CrCl ≥ 50 mL/min (n = 5326, 78%) and renal dysfunction group with CrCl < 50 mL/min (n = 1480, 22%). In the normal renal function group, 1609 (30%) received 10 mg/day (under-dose), while in the renal dysfunction group, 108 (7%) received 15 mg/day (over-dose). In the normal renal function group, under-dose of rivaroxaban was associated with higher all-cause mortality, while in the renal dysfunction group, over-dose was associated with higher incidence of major bleeding. In contrast, the incidence of stroke or systemic embolism was not different between the 2 groups regardless of the dose of rivaroxaban. In the propensity score matched analysis to adjust the difference in characteristics according to doses of rivaroxaban, the incidences of clinical outcomes were comparable between the 2 dose groups in both renal function groups. These results indicate that the dose of rivaroxaban should be reduced depending on the renal function, considering the balance between risks of bleeding and ischemia.
No takes yet. Share an insight, caveat, or question.
Atarashi et al. (2021) conducted an observational in Non-valvular atrial fibrillation (n=6,806). Renal dysfunction (CrCl < 50 mL/min) vs. Normal renal function (CrCl ≥ 50 mL/min) was evaluated on Stroke or systemic embolism (p=<0.001). In Japanese patients with non-valvular atrial fibrillation treated with rivaroxaban, renal dysfunction was associated with a higher incidence of stroke or systemic embolism compared to normal renal function.
Synapse has enriched 10 related papers. Consider them for comparative context: